The influence of TNIK gene polymorphisms on risperidone response in a Chinese Han population

Pharmacogenomics. 2022 Jul;23(10):575-583. doi: 10.2217/pgs-2022-0052. Epub 2022 Jun 14.

Abstract

Aim: To investigate whether the TNIK gene affects risperidone treatment outcomes in the Chinese population. Methods: A total of 148 unrelated inpatients who received risperidone for six weeks were enrolled. The selected single nucleotide polymorphisms (SNPs; rs2088885, rs7627954 and rs13065441) were genotyped using the MassARRAY® SNP IPLEX platform. Results: The analysis showed that one novel SNP of TNIK, rs7627954, had a significant association with the response to risperidone (χ2 = 4.472; p = 0.034). This work also identified rs2088885 as significantly associated with risperidone response (χ2 = 5.257; p = 0.022). The result revealed that the rs2088885-rs7627954 C-T haplotype was more prevalent in good responders than in poor responders (p = 0.0278). Conclusion: This study revealed that the rs2088885 and rs7627954 SNPs of TNIK are associated with risperidone treatment response.

Keywords: TNIK; antipsychotics; pharmacogenetics; risperidone response; schizophrenia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antipsychotic Agents* / therapeutic use
  • China
  • Genetic Predisposition to Disease
  • Humans
  • Polymorphism, Single Nucleotide / genetics
  • Protein Serine-Threonine Kinases / genetics*
  • Risperidone / therapeutic use
  • Schizophrenia* / drug therapy

Substances

  • Antipsychotic Agents
  • Protein Serine-Threonine Kinases
  • TNIK protein, human
  • Risperidone